Cancerguard
Innovative multi-cancer early detection test
Company profile
Helping people live fuller lives through better health by transforming cancer detection, diagnosis and management
Company profile
Exact Sciences is a leading molecular diagnostics company dedicated to eradicating cancer through prevention, early detection, and personalized treatment guidance. Founded in 1995 and headquartered in Madison, Wisconsin, the company has grown to serve over 120 countries with more than 6,500 employees globally. Exact Sciences develops and commercializes innovative cancer tests that explore hereditary risks, screen for cancer's presence, and examine the unique genomic alterations of an individual's cancer to help guide treatment decisions. The company's portfolio includes the widely-adopted Cologuard colorectal cancer screening test, the Oncotype DX suite of genomic tests for breast and colon cancer treatment guidance, and newer innovations like the Cancerguard multi-cancer early detection test. With nine research and development centers and state-of-the-art laboratories, Exact Sciences combines rigorous research, deep clinical expertise, and proven accuracy to deliver life-changing diagnostic solutions. The company has tested over 4 million people in 2023 alone and maintains strong collaborations with leading medical institutions, advocacy partners, and policymakers. Exact Sciences went public in February 2001 and has been certified as a Great Place to Work for seven consecutive years, reflecting its commitment to innovation, integrity, quality, teamwork, and accountability in the fight against cancer.
Company description Exact Sciences official website
Mission. We're united by a shared purpose: helping people live fuller lives through better health. We're committed to answering questions, solving problems, and making a lasting, positive impact on people's lives.
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Other deployment with recorded integration context.
Company milestones
Launch of three innovative cancer tests in 2025; Publication of BLUE-C study results in 2024; OncoExTra cancer therapy selection test launch in 2023; PreventionGenetics acquisition in 2022
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Innovative multi-cancer early detection test
Non-invasive colorectal cancer screening test
Enhanced colorectal cancer screening test
Molecular residual disease detection test
Cancer therapy selection test
Liver cancer screening test
Genomic test for ductal carcinoma in situ
Genomic test for breast cancer treatment decisions
Genomic test for colon cancer recurrence risk
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Journal of medical economics · Dec 1, 2026
Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.Journal of medical economics · Dec 1, 2026
Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model.BMJ open · Sep 16, 2026
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.JCO precision oncology · Sep 1, 2026
Investigating languishing in North American genetic counselors.Journal of genetic counseling · Aug 1, 2026
Yield of Synchronous Adenomas and Serrated Polyps in Patients With Positive Stool Tests (mt-sDNA or FIT): Data From the New Hampshire Colonoscopy Registry.JGH open : an open access journal of gastroenterology and hepatology · Aug 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Age-weighted to U.S. population for adults with no colorectal neoplasia
Global testing volume
ALPHA-CORRECT study investigating ctDNA association with recurrence in stage III colorectal cancer
Demonstrated association of ctDNA with recurrence risk using Oncodetect test
Genomic testing helped guide treatment decision to forgo chemotherapy for breast cancer
Informed decision to forgo chemotherapy based on genomic test results
At-home testing enabled early detection and treatment of colon cancer before progression
Early detection and treatment of colon cancer before progression
BETA-CORRECT study investigating ctDNA association with recurrence in stage II-IV colorectal cancer
Demonstrated association of ctDNA with recurrence at pre-specified timepoints using Oncodetect test
05 · Leadership
Leadership profiles and professional links from the current Company record.
Kevin Conroy
CEO
06 · Company updates
Recent articles published on Exact Sciences's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.